Scholarlink

Aim and purpose <p>This study aimed to investigate the relationship between myeloma cell maturity, clinical profiles, and treatment outcomes in patients with multiple myeloma (MM).</p> Patients and methods <p>The J-CHARGE-MM database includes data from 1200 MM patients diagnosed between January 2011 and January 2023. Immunophenotyping by flow cytometry using antibodies against CD38, CD49e, and MPC-1 was used to evaluate myeloma cell maturity.</p> Results <p>Out of 969 patients evaluable for myeloma cell maturity, 115 were classified as mature type, 626 as intermediate type, and 228 as immature type. Patients with the immature type were more likely to have the IgG type and 1q21 gain/amplification. Treatment response and outcome analysis showed that patients with the immature type had lower response rates and worse time to next treatment (TTNT) with bortezomib-based therapy compared to those with the mature or intermediate type. Lenalidomide-based therapy partially mitigated the adverse impact of the immature type. However, daratumumab combination therapy showed higher response rates and better TTNT, which was almost equivalent between the mature/intermediate and immature types.</p> Conclusion <p>Stratifying patients with MM based on myeloma cell maturity provides meaningful information for choosing the best treatment strategy and improving patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group

  • 期刊论文

  • 发表日期：

    2025年11月9日

查看全文
  • Noriyoshi Iriyama,
  • Hitomi Nakayama,
  • Masaru Nakagawa,
  • Atsushi Takahata,
  • Eriko Sato,
  • Motoki Takano,
  • Keigo Okada,
  • Kohtaro Toyama,
  • Toshiaki Hayashi,
  • Takashi Abe,
  • Keisuke Tanaka,
  • Yasuhiko Senpuku,
  • Yuki Osada,
  • Junichi Watanabe,
  • Koh Yamamoto,
  • Yasunobu Sekiguchi,
  • Gaku Oshikawa,
  • Yuta Kimura,
  • Michihide Tokuhira,
  • Ken Suzuki,
  • Takashi Kumagai,
  • Takayuki Ikezoe,
  • Shigeo Toyota,
  • Katsuhiro Miura,
  • Tomonori Nakazato,
  • Takehiko Mori

摘要

Aim and purpose

This study aimed to investigate the relationship between myeloma cell maturity, clinical profiles, and treatment outcomes in patients with multiple myeloma (MM).

Patients and methods

The J-CHARGE-MM database includes data from 1200 MM patients diagnosed between January 2011 and January 2023. Immunophenotyping by flow cytometry using antibodies against CD38, CD49e, and MPC-1 was used to evaluate myeloma cell maturity.

Results

Out of 969 patients evaluable for myeloma cell maturity, 115 were classified as mature type, 626 as intermediate type, and 228 as immature type. Patients with the immature type were more likely to have the IgG type and 1q21 gain/amplification. Treatment response and outcome analysis showed that patients with the immature type had lower response rates and worse time to next treatment (TTNT) with bortezomib-based therapy compared to those with the mature or intermediate type. Lenalidomide-based therapy partially mitigated the adverse impact of the immature type. However, daratumumab combination therapy showed higher response rates and better TTNT, which was almost equivalent between the mature/intermediate and immature types.

Conclusion

Stratifying patients with MM based on myeloma cell maturity provides meaningful information for choosing the best treatment strategy and improving patient outcomes.